Last updated: May 27, 2026
Executive summary
- NERATINIB MALEATE is supplied commercially as the oral anticancer drug neratinib (distinctly marketed under brands such as Nerlynx in the US). Supply in the market is split between (1) neratinib active pharmaceutical ingredient (API) manufacturers and (2) finished-dose manufacturers and packaging sites for clinical and commercial tablets/capsules.
- Publicly indexed “supplier” information for neratinib is fragmented across FDA drug labeling, regulatory CMC documents (summaries), and contract manufacturing announcements. Without a defined target market (US/EU/ROW), dosage form, and whether the request means “API” versus “finished product,” a complete supplier list cannot be produced with the level of specificity required for IP, licensing, and sourcing decisions.
What companies supply neratinib maleate API and finished drug product?
Answer: Neratinib maleate supply is typically handled through a mix of (a) branded drug manufacturers and (b) API and tablet/capsule contract manufacturers. The core branded commercial supplier is tied to the product holder for neratinib (Nerlynx in the US).
What neratinib maleate is labeled as in the FDA/labeling supply chain?
- Oral neratinib products are manufactured and labeled with specific manufacturer/packager sites on prescribing information and associated FDA labeling.
- For supplier identification, the actionable distinction is between:
- API site for neratinib (API manufacturer)
- Finished-dose site for tablets/capsules (drug product manufacturer)
- Packaging and distribution sites (packager/labeler)
Common neratinib maleate dosing forms in commerce
- Oral solid dosage forms (labeling-driven: tablets/capsules depending on the market and product configuration).
- Source for “which supplier makes which strength and dosage form” is the product’s FDA/labeling section identifying manufacturer and packager.
Which API manufacturers make neratinib (neratinib maleate) for contract supply?
Answer: API supply is commonly outsourced to specialized small-molecule API manufacturers with validated synthesis routes, analytical release, and controlled impurity profiles.
What to look for in real supplier lists (API)
- Site-level manufacturing address in regulatory CMC summaries or compendial/labeling references
- Vendor role: “manufactured by,” “distributed by,” “packaged by,” or “tested by”
- Salt form handling for “maleate” (often reflected in analytical methods and release specifications)
Who makes and packages neratinib tablets/capsules (finished-dose suppliers)?
Answer: Finished-dose suppliers are the drug-product manufacturing and packaging sites named in the product labeling and FDA records for the marketed strengths.
How to map finished-dose suppliers by strength
- Each strength can have different packaging configurations and sometimes different packager sites even when the API manufacturer stays constant.
- Supplier lists should tie to exact NDC/strength configurations.
What contract manufacturing patterns occur for neratinib
- Tablets/capsules are typically manufactured under GMP with:
- blend uniformity and content uniformity controls
- dissolution/impurity controls aligned with the neratinib impurity profile
- packaging designed for moisture and light stability where relevant
How do sourcing obligations differ by region for neratinib maleate?
Answer: US supply arrangements are governed by the FDA-labeled manufacturer/packager; EU supply arrangements are governed by EMA dossiers and national competent authority documentation for the authorized product.
US vs EU supplier identification differences
- US: prescribing information and FDA labeling often list manufacturer/packager entities explicitly.
- EU: marketing authorization dossier and national packaging authorization can differ by country and sometimes show different local labeling entities.
What supplier constraints create shortages or lead-time risk for neratinib maleate?
Answer: For oncology small molecules, supply risk typically concentrates in:
- API batch availability (fewer qualified API sites)
- single-site tablet/capsule drug product manufacturing
- long-cycle synthesis steps and impurity control
- regulatory holds affecting one strength’s release
Key lead-time risks in neratinib supply chains
- API synthesis dependence on specialized intermediates
- analytical method transfer timelines for contract sites
- QP release bottlenecks for the drug-product stage in EU markets
What patents or exclusivity issues affect supplier entry for neratinib maleate?
Answer: Neratinib has strong patent and data exclusivity barriers that typically limit generic and biosimilar-style competition, concentrating supply among fewer authorized commercial and contract partners during exclusivity windows.
Why this matters to supplier selection
- Even when contract manufacturing capacity exists, suppliers may not be able to run clinical or commercial production for non-authorized versions during active exclusivity without licensing.
- This concentrates commercial supply into the branded ecosystem.
Key Takeaways
- A complete, auditable list of “suppliers for NERATINIB MALEATE” requires a defined scope: API vs finished dose, and the target jurisdiction plus strength/dosage form.
- In practice, the most actionable supplier identifiers are the labeled API manufacturer, finished-dose manufacturer, and packager/labeler sites named in FDA/EMA authorization artifacts tied to the exact NDC/strength configuration.
- Neratinib supply risk tends to concentrate in API synthesis capacity and the single-digit number of qualified drug-product manufacturing and packaging sites.
FAQs
- How can I identify the API supplier for neratinib maleate from regulatory labeling?
- Which neratinib strengths share the same finished-dose manufacturer and which change packager sites?
- Who are the likely contract manufacturing partners for neratinib tablets/capsules versus the API manufacturers?
- Do neratinib maleate supply chains differ materially between US and EU markets?
- What practical steps mitigate lead-time and batch-release risk when sourcing neratinib maleate?
References
- FDA Prescribing Information for marketed neratinib products (Nerlynx) and associated FDA labeling records.
- EMA product information and assessment documentation for authorized neratinib marketing authorizations.
